ChemoCentryx (NASDAQ:CCXI) and Adamis Pharmaceuticals (NASDAQ:ADMP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends and institutional ownership.
This table compares ChemoCentryx and Adamis Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares ChemoCentryx and Adamis Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|ChemoCentryx||$82.50 million||6.36||$18.19 million||$0.36||28.86|
|Adamis Pharmaceuticals||$13.07 million||10.20||-$25.53 million||($0.90)||-3.13|
ChemoCentryx has higher revenue and earnings than Adamis Pharmaceuticals. Adamis Pharmaceuticals is trading at a lower price-to-earnings ratio than ChemoCentryx, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
ChemoCentryx has a beta of 1.78, meaning that its stock price is 78% more volatile than the S&P 500. Comparatively, Adamis Pharmaceuticals has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.
Insider and Institutional Ownership
53.8% of ChemoCentryx shares are owned by institutional investors. Comparatively, 22.4% of Adamis Pharmaceuticals shares are owned by institutional investors. 14.5% of ChemoCentryx shares are owned by insiders. Comparatively, 10.2% of Adamis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This is a breakdown of recent ratings for ChemoCentryx and Adamis Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ChemoCentryx currently has a consensus price target of $17.10, suggesting a potential upside of 64.58%. Adamis Pharmaceuticals has a consensus price target of $7.38, suggesting a potential upside of 156.97%. Given Adamis Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Adamis Pharmaceuticals is more favorable than ChemoCentryx.
ChemoCentryx beats Adamis Pharmaceuticals on 11 of the 15 factors compared between the two stocks.
ChemoCentryx Company Profile
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company is also developing Avacopan for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS), and in atypical hemolytic uremic syndrome (aHUS). In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy (DN) and is being developed for patients with focal segmental glomerulosclerosis (FSGS). Further, it has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases, and in cancer. The company was founded in 1997 and is headquartered in Mountain View, California.
Adamis Pharmaceuticals Company Profile
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company’s specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of albuterol (APC-2000) for the treatment of bronchospasms; fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered dose inhaler product for the asthma; and naloxone injection product candidates (APC-6000) for the treatment of opioid overdose. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, ophthalmic preparations, topical compounds for pain, and men’s and women’s health products; and certain veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California.
Receive News & Ratings for ChemoCentryx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ChemoCentryx and related companies with MarketBeat.com’s FREE daily email newsletter.